U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H21N3O2
Molecular Weight 287.3574
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOLMITRIPTAN

SMILES

CN(C)CCc1c[nH]c2ccc(C[C@@]3([H])COC(=N3)O)cc12

InChI

InChIKey=ULSDMUVEXKOYBU-ZDUSSCGKSA-N
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H21N3O2
Molecular Weight 287.3574
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9154322

Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and moderate affinity for 5-HT1A receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Zomig for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction, and inhibition of pro-inflammatory neuropeptide release.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ZOMIG

Approved Use

INDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1)

Launch Date

8.80416E11
Palliative
ZOMIG

Approved Use

INDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1)

Launch Date

8.80416E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.8 ng/mL
0.925 mg single, intravenous
dose: 0.925 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.3 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.8 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
4.4 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
5.6 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 ng/mL
1.475 mg single, intravenous
dose: 1.475 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
10.6 ng/mL
1.85 mg single, intravenous
dose: 1.85 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
9.9 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.2 ng/mL
2.95 mg single, intravenous
dose: 2.95 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.8 ng × h/mL
0.925 mg single, intravenous
dose: 0.925 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.7 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
21.3 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
23.9 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
30.9 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
32.4 ng × h/mL
1.475 mg single, intravenous
dose: 1.475 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
32.5 ng × h/mL
1.85 mg single, intravenous
dose: 1.85 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
54.8 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
55.7 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
71.2 ng × h/mL
2.95 mg single, intravenous
dose: 2.95 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.1 h
0.925 mg single, intravenous
dose: 0.925 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.29 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.56 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.6 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.5 h
1.475 mg single, intravenous
dose: 1.475 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.32 h
1.85 mg single, intravenous
dose: 1.85 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.82 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.66 h
2.95 mg single, intravenous
dose: 2.95 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLMITRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
75%
unknown, unknown
ZOLMITRIPTAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg single, intranasal
Highest studied dose
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources: Page: p.845
unhealthy, 41.7 ± 10.4
n = 783
Health Status: unhealthy
Condition: Migraine
Age Group: 41.7 ± 10.4
Sex: M+F
Population Size: 783
Sources: Page: p.845
Disc. AE: Taste abnormality, Migraine aggravated...
AEs leading to
discontinuation/dose reduction:
Taste abnormality (0.4%)
Migraine aggravated (0.4%)
Sources: Page: p.845
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources: Page: p.13
unhealthy
Other AEs: Sedation...
5 mg single, oral (max)
Recommended
unhealthy
Disc. AE: Arrhythmia, Cerebral hemorrhage...
AEs leading to
discontinuation/dose reduction:
Arrhythmia
Cerebral hemorrhage
Subarachnoid hemorrhage
Stroke
Gastrointestinal ischemia
Peripheral vasoconstriction
Serotonin syndrome
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Migraine aggravated 0.4%
Disc. AE
5 mg single, intranasal
Highest studied dose
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources: Page: p.845
unhealthy, 41.7 ± 10.4
n = 783
Health Status: unhealthy
Condition: Migraine
Age Group: 41.7 ± 10.4
Sex: M+F
Population Size: 783
Sources: Page: p.845
Taste abnormality 0.4%
Disc. AE
5 mg single, intranasal
Highest studied dose
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources: Page: p.845
unhealthy, 41.7 ± 10.4
n = 783
Health Status: unhealthy
Condition: Migraine
Age Group: 41.7 ± 10.4
Sex: M+F
Population Size: 783
Sources: Page: p.845
Sedation
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources: Page: p.13
unhealthy
Arrhythmia Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Cerebral hemorrhage Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Gastrointestinal ischemia Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Peripheral vasoconstriction Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Serotonin syndrome Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Stroke Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Subarachnoid hemorrhage Disc. AE
5 mg single, oral (max)
Recommended
unhealthy
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
yes
yes (co-administration study)
Comment: The increased exposure to zolmitriptan and 183C91 by cimetidine indicated that a reduction in the total daily recommended dose of zolmitriptan may be necessary when treating migraine patients who are taking nonspecific cytochrome P450 inhibitors or specific cytochrome 1A2 inhibitors. (https://pubmed.ncbi.nlm.nih.gov/18370509/)
Page: 26.0
Drug as victim
PubMed

PubMed

TitleDatePubMed
Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
1997 Oct
Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat.
1998 Jan
Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.
1998 Jun
[Mechanism of action of zolmitriptan].
1998 Oct
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
1999 Jun
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
2000 Oct
Global trends in migraine care: results from the MAZE survey.
2002
Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.
2002
Transcranial Doppler in migraine attacks before and after treatment with oral zolmitriptan or sumatriptan.
2003 Jan
Cost considerations of acute migraine treatment.
2004 Mar
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
2005 Mar
Myocardial infarction after taking zolmitriptan.
2005 May
Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors.
2005 May
Myalgia and cramps associated with zolmitriptan.
2005 Sep-Oct
Renal infarction during the use of rizatriptan and zolmitriptan: two case reports.
2006
Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet.
2006 Dec
Molecular drug targets and structure based drug design: A holistic approach.
2006 Dec 23
Acute renal failure in a 17-year-old female with ALL receiving escalating intravenous methotrexate without leukovorin.
2007 Aug
The 1:1 inclusion compounds zolmitriptan-benzene and zolmitriptan-phenol.
2007 Jul
Triptans and troponin: a case report.
2009 Jun 18
Patents

Sample Use Guides

The recommended starting dose of ZOMIG (zolmitriptan) is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of ZOMIG is 5 mg.
Route of Administration: Oral
Stimulation of a Ca(2+)-dependent K(+) current by zolmitriptan was investigated in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Outward K(+) currents (I(K)) were examined in non-transfected C6 glioma cells and in cells expressing cloned human 5-HT(1B) receptors using the patch-clamp technique in the whole-cell configuration. In C6 glioma cells expressing recombinant human 5-HT 1B) receptor, zolmitriptan increased I(K) in a concentration-dependent manner (maximum increase 16.3+/-7.8%, n=5, p<0.001) with a pD(2) value (geometric mean with 95% confidence intervals) of 7.03 (7.90-6.10). Zolmitriptan failed to elicit increases in I(K) in non-transfected C6 cells.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:08:12 UTC 2021
Edited
by admin
on Fri Jun 25 21:08:12 UTC 2021
Record UNII
2FS66TH3YW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOLMITRIPTAN
INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
311-C-90
Code English
ZOLMITRIPTAN [WHO-DD]
Common Name English
ZOLMITRIPTAN [USAN]
Common Name English
ZOLMITRIPTAN [INN]
Common Name English
ZOLMITRIPTAN [MART.]
Common Name English
ZOLMITRIPTAN [EP MONOGRAPH]
Common Name English
ZOLMITRIPTAN [MI]
Common Name English
ZOLMITRIPTAN [ORANGE BOOK]
Common Name English
311C90
Code English
ZOLMITRIPTAN [VANDF]
Common Name English
2-OXAZOLIDINONE, 4-((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)-, (S)-
Systematic Name English
ZOLMITRIPTAN [JAN]
Common Name English
CVT-427
Common Name English
(S)-4-((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)-2-OXAZOLIDINONE
Systematic Name English
ZOLMITRIPTAN [USP MONOGRAPH]
Common Name English
ZOLMITRIPTAN [USP-RS]
Common Name English
NSC-760383
Code English
ZOMIG
Brand Name English
Classification Tree Code System Code
WHO-VATC QN02CC03
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
NCI_THESAURUS C47794
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
NDF-RT N0000175763
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
NDF-RT N0000175765
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
WHO-ATC N02CC03
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
LIVERTOX 1052
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
NDF-RT N0000175764
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
Code System Code Type Description
FDA UNII
2FS66TH3YW
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
PUBCHEM
60857
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY
CAS
139264-17-8
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
INN
7408
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
LACTMED
Zolmitriptan
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
IUPHAR
60
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
DRUG CENTRAL
2869
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
USP_CATALOG
1727009
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
ZOLMITRIPTAN
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY
DRUG BANK
DB00315
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
NCI_THESAURUS
C47789
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY
MESH
C089750
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY
EPA CompTox
139264-17-8
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
RXCUI
135775
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY RxNorm
EVMPD
SUB00181MIG
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
MERCK INDEX
M11660
Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1185
Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BINDER->LIGAND
BINDING
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
METABOLITE INACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC